Larimar Therapeutics, Inc. (LRMR)
NASDAQ: LRMR · Real-Time Price · USD
3.880
+0.130 (3.47%)
At close: Jul 25, 2025, 4:00 PM
3.850
-0.030 (-0.77%)
After-hours: Jul 25, 2025, 7:56 PM EDT
Larimar Therapeutics Employees
Larimar Therapeutics had 65 employees as of December 31, 2024. The number of employees increased by 23 or 54.76% compared to the previous year.
Employees
65
Change (1Y)
23
Growth (1Y)
54.76%
Revenue / Employee
n/a
Profits / Employee
-$1,465,092
Market Cap
248.43M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 65 | 23 | 54.76% |
| Dec 31, 2023 | 42 | 16 | 61.54% |
| Dec 31, 2022 | 26 | -5 | -16.13% |
| Dec 31, 2021 | 31 | 3 | 10.71% |
| Dec 31, 2020 | 28 | 12 | 75.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
LRMR News
- 18 days ago - Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich's Ataxia - GlobeNewsWire
- 4 weeks ago - Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich's Ataxia Program - GlobeNewsWire
- 5 weeks ago - Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia - GlobeNewsWire
- 3 months ago - Larimar Therapeutics Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 4 months ago - Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 5 months ago - Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference - GlobeNewsWire
- 6 months ago - Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia - GlobeNewsWire
- 7 months ago - Larimar Therapeutics: Positive Friedreich's Ataxia Data Can Only Get Better - Seeking Alpha